Agenus Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $364.1M
- Price
- $8.09
- % Change (Daily % change from the live per-ticker quote feed.)
- +8.01%
- Volume
- 1.5M
About
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
Quick stats
Shares outstanding45.0M
Computed float38.9M
Float / shares86.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001098972
Websitehttps://www.agenusbio.com
AI Summary
AI-generated1/50
majorbullishearnings
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Agenus reported Q2 2026 revenue of $34.5 million, up from $25.7 million in the prior year, driven by $6.4 million in pre-commercial product revenue for BOT+BAL and $28.1 million in non-cash royalties. The company narrowed its net loss to $0.6 million compared to a $30 million loss in Q2 2025.
The company closed an oversubscribed private placement in July, securing $85 million in gross proceeds with warrants for up to an additional $255 million. This financing is expected to support operations and the execution of the ROBBIN trial into 2027 and beyond if warrants are fully exercised.
Agenus is prioritizing resources for the Phase 3 ROBBIN trial in neoadjuvant MSS colon cancer, with initiation and first patient dosing anticipated in Q1 2027. Consequently, the company discontinued funding for the BATTMAN trial in refractory metastatic colorectal cancer to focus on the ROBBIN program, which targets a U.S. market opportunity estimated at over $7 billion annually.
Red flags
- Discontinued funding for BATTMAN Phase 3 trial to prioritize ROBBIN
- Cash balance was $18.7 million at quarter end prior to $85 million financing close
- Non-cash royalty revenue accounted for majority ($28.1M) of $34.5M total revenue